Orlistat, the active ingredient of Alli, is a lipase inhibitor used for weight management in adults with obesity or excess weight. It works inside the digestive tract by reducing the amount of…
Orlistat, the active ingredient of Alli, is a lipase inhibitor used for weight management in adults with obesity or excess weight. It works inside the digestive tract by reducing the amount of dietary fat absorbed from meals. Alli is taken as oral capsules alongside a reduced-calorie, lower-fat eating plan.
Alli contains orlistat, a gastrointestinal lipase inhibitor classified under ATC code A08AB01. Its therapeutic area is weight management in adults whose body mass index indicates obesity or clinically significant excess weight.
Alli contains orlistat, a gastrointestinal lipase inhibitor classified under ATC code A08AB01. Its therapeutic area is weight management in adults whose body mass index indicates obesity or clinically significant excess weight. The medicine works locally in the stomach and small intestine rather than producing a stimulant effect on the brain.
Orlistat is designed for use with dietary changes. It does not suppress appetite directly, and it does not remove all dietary fat from a meal. Its role is to reduce the absorption of part of the fat eaten, which lowers calorie absorption when the diet is also controlled. The amount and frequency of use depend on the purpose of treatment and are agreed with a doctor or pharmacist. Alli is supplied as oral capsules.
Its therapeutic area is weight management in adults whose body mass index indicates obesity or clinically significant excess weight.
Alli capsules are taken by mouth with meals that contain fat or shortly afterwards. The medicine should be used with a reduced-calorie diet in which fat is distributed across the main meals rather than concentrated in one large serving.
Practical points include:
The treatment is intended to support sustained weight management. It works poorly when meals remain high in fat, and digestive side effects may become difficult to control in that situation.
Alli is not suitable for people with chronic malabsorption syndrome or cholestasis. Chronic malabsorption syndrome prevents normal nutrient absorption, while cholestasis involves impaired bile flow. Orlistat can worsen nutritional problems or become inappropriate when fat digestion is already seriously impaired.
This medication is not for you if:
People with diabetes may need closer monitoring because weight loss can alter blood-glucose control and the required doses of antidiabetic treatment. Anyone with kidney disease should mention this before use, since rare kidney-related complications have been reported with orlistat-containing treatment.
Severe or persistent abdominal pain, yellowing of the skin or eyes, dark urine, marked weakness, a widespread rash, facial swelling, or breathing difficulty requires urgent medical assessment.
Digestive effects are the most characteristic adverse reactions associated with Alli. They arise because some dietary fat remains undigested and reaches the lower bowel.
Common effects include:
These effects often become more noticeable after a high-fat meal. They may improve when dietary fat is reduced and distributed evenly between meals. Repeated urgency can interfere with work, commuting, or sleep, so the pattern should be addressed rather than ignored.
Rare but serious problems require prompt assessment. These include symptoms suggesting liver injury, severe allergic reaction, severe abdominal pain, or kidney complications. Persistent diarrhoea can also contribute to dehydration, especially in older adults or people taking diuretics.
One practical detail is easy to underestimate: oily leakage can occur without much warning. People starting treatment often keep spare underwear or absorbent protection available until they understand how their body responds.
Orlistat binds to gastric and pancreatic lipases in the digestive tract. These enzymes normally split dietary triglycerides into smaller molecules that can cross the intestinal wall. When orlistat blocks the enzymes, part of the fat remains undigested and passes through the bowel instead of being absorbed.
The effect is local. Only a small amount of orlistat reaches the circulation, so its main action takes place within the intestinal lumen. This mechanism differs from appetite-focused treatments, which act through central nervous system or hormonal pathways.
The unabsorbed fat explains the characteristic gastrointestinal effects. Oily spotting, increased bowel frequency, flatulence with discharge, and faecal urgency can occur when meals contain more fat than the treatment plan allows. The European Medicines Agency describes these effects as predictable consequences of lipase inhibition rather than signs that the medicine is working systemically [1].
Several practical errors can make Alli seem ineffective or unnecessarily difficult to tolerate.
A common misunderstanding involves the phrase “fat blocking”. Orlistat does not prevent absorption of every calorie, protein, carbohydrate, or nutrient. Its principal effect concerns part of the fat consumed in a meal.
The closest alternative by mechanism is prescription-strength orlistat. Both approaches inhibit gastrointestinal lipases, but they may differ in strength, regulatory status, and the level of clinical supervision required.
| Approach | Mechanism | Practical distinction |
|---|---|---|
| Alli | Orlistat-mediated lipase inhibition | Non-prescription weight-management option for eligible adults, used with dietary control |
| Prescription-strength orlistat | Orlistat-mediated lipase inhibition | Higher-strength treatment used under prescribing supervision |
| Appetite-focused treatment | Central or hormonal appetite regulation | Works through a different pathway and has a different interaction and monitoring profile |
The main advantage of orlistat is its local digestive mechanism, which avoids the stimulant effects associated with some appetite-suppressing approaches. Its limitation is equally clear: gastrointestinal adverse effects can be inconvenient, especially when meals contain substantial fat.
The choice between treatment approaches depends on body mass index, existing conditions, current medicines, previous weight-management attempts, and the degree of clinical monitoring required.
In clinical practice, doctors usually present orlistat as a tool that works only when meal composition changes with it. The medicine does not compensate for unrestricted high-fat eating. A person who eats a large fatty meal may experience more adverse effects without gaining a greater therapeutic benefit.
A physician will also look beyond body weight. Blood pressure, glucose control, lipid levels, mobility, sleep, and waist measurement can all help show whether weight management is producing meaningful health improvement. The scale is useful, but it is not the only outcome.
Consistency matters because sporadic use produces an inconsistent reduction in fat absorption. Missed doses should not be replaced with extra capsules. The treatment plan should also be reviewed if weight loss does not develop or if side effects interfere with normal activities.
Patients sometimes expect appetite to disappear. That is not how orlistat works. Hunger may remain, while the medicine changes how much fat from food enters the circulation.
Orlistat acts on the fat present in the meal associated with the dose, rather than creating a long-lasting appetite effect. Its influence is linked to digestion and intestinal lipase activity, so the practical effect relates to the meal period rather than a full day of appetite control. The European Medicines Agency’s product information describes this local digestive mechanism in its European assessment documents from 2007 [2]. A meal without fat does not produce the same need for lipase inhibition.
Alli is not intended to cause sedation or a stimulant effect, so direct impairment of concentration is not expected from its mechanism. Urgency, diarrhoea, or abdominal discomfort can still make driving or machinery work difficult in practice. Guidance from the HPRA in its medicine-safety framework from 2024 supports considering functional effects from adverse reactions, even when a medicine does not directly impair alertness [3]. Avoid driving if sudden bowel symptoms make it unsafe to remain in control of a vehicle.
Alli is taken with a main meal that contains fat or shortly after that meal. It is not used to replace a meal, and a fat-free meal does not require the same approach. The European Commission’s medicinal-product information for orlistat from 2007 describes administration in relation to meals and dietary fat [4]. Taking the capsule with a very high-fat meal increases the likelihood of oily stool and urgency.
Urgent medical assessment is needed for yellowing of the skin or eyes, dark urine, severe or persistent abdominal pain, facial swelling, breathing difficulty, or a widespread blistering rash. Severe weakness, reduced urine output, or signs of dehydration also require prompt attention. The World Health Organization’s pharmacovigilance guidance from 2022 treats suspected serious or unexpected reactions as events requiring timely clinical evaluation [5]. Do not take further doses while awaiting urgent advice if a serious allergic or liver-related reaction is suspected.
The closest pharmacological alternative is prescription-strength orlistat, which uses the same lipase-inhibition mechanism but may involve a different strength and closer prescribing supervision. Appetite-focused medicines work through different central or hormonal pathways and may have different contraindications and interactions. NICE obesity guidance from 2023 places medicine use within a wider plan involving diet, activity, follow-up, and response assessment. The most suitable option depends on medical history, body mass index, current medicines, and tolerability.
Older adults may use orlistat when a clinician or pharmacist considers the treatment appropriate, but medicine review is important. Kidney function, hydration, diabetes treatment, anticoagulation, thyroid therapy, and vitamin absorption may need attention. The EMA geriatric principles described in its 2018 scientific guidance support individual assessment when age-related changes can alter medicine safety. Persistent diarrhoea or reduced food intake may be more troublesome in an older person, especially when other medicines increase dehydration risk.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 5 reviews
He used Alli with smaller meals for several weeks. Weight loss was gradual, but oily spotting occurred after takeaway food, so he stopped choosing high-fat meals at work.
Several weeks 7 Oct 2026She found the capsules manageable when meals were planned in advance. The first week included urgency and loose stools, and she felt the treatment was too inconvenient until she reduced the fat in breakfast and lunch.
The first week 16 Oct 2026He reported better control of portion sizes after starting a structured eating plan alongside Alli. He did not notice a rapid change on the scales and was disappointed during the first fortnight.
The first fortnight 22 Oct 2026She used the treatment while taking other regular medicines. A medication review was arranged before continued use, and vitamin timing became part of her daily routine.
28 Oct 2026He experienced flatulence with discharge after a rich evening meal. The symptom settled when he spread fat more evenly through the day, although he still preferred to avoid taking the capsules before social events.
4 Nov 2026
